ST. LOUIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Cowen 43rd Annual Health Care Conference.
Mr. Fischel will present on Stereotaxis’ business and technology during a Fireside Discussion with Josh Jennings, Cowen’s Managing Director & Senior Research Analyst, on Monday, March 6, 2023, at 11:10 am ET. Mr. Fischel will be available for one-on-one meetings the remainder of the day.
“We look forward to joining Cowen and sharing Stereotaxis’ differentiated technology, clinical value, and growth strategy with investors,” says Mr. Fischel.
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.03 |
| Daily Change: | 0.008 0.40 |
| Daily Volume: | 38,740 |
| Market Cap: | US$171.830M |
March 10, 2025 March 03, 2025 March 03, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
